- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06096779
Une étude évaluant l'atezolizumab, avec ou sans bevacizumab, chez des patients atteints d'un carcinome hépatocellulaire non résécable et d'une cirrhose de Child-Pugh B7 et B8 (Kirros)
Une étude de phase II, ouverte, multicohorte et multicentrique chez des patients atteints d'un carcinome hépatocellulaire non résécable et d'une cirrhose de Child-Pugh B7 et B8
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Rio Piedras, Porto Rico, 00935
- Pan American Center for Oncology Trials, LLC
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla, California, États-Unis, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, États-Unis, 90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach, California, États-Unis, 92663
- University of Southern California
-
Orange, California, États-Unis, 92868
- University of California Irvine Medical Center
-
Pasadena, California, États-Unis, 91105-2561
- California Liver Research Institute
-
Sacramento, California, États-Unis, 95817
- University of California Davis Medical Center
-
Stanford, California, États-Unis, 94305
- Stanford Health Care
-
Torrance, California, États-Unis, 90502-2006
- Harbor UCLA Medical Center
-
West Hollywood, California, États-Unis, 90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford, Connecticut, États-Unis, 06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20037
- George Washington University- Medical Faculty Associates
-
Washington D.C., District of Columbia, États-Unis, 20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando, Florida, États-Unis, 32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611-2908
- Northwestern University
-
Chicago, Illinois, États-Unis, 60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago, Illinois, États-Unis, 60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70805
- LSU Health Baton Rouge
-
Baton Rouge, Louisiana, États-Unis, 70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, États-Unis, 02111
- Tufts Medical Center
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis, 08901
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, États-Unis, 07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola, New York, États-Unis, 11501-4064
- NYU Langone Hospital - Long Island
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, États-Unis, 10467
- Montefiore Medical Center
-
The Bronx, New York, États-Unis, 10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton, Ohio, États-Unis, 45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro, Oregon, États-Unis, 97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland, Oregon, États-Unis, 97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Jefferson Health Honickman Center
-
Pittsburgh, Pennsylvania, États-Unis, 15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown, Tennessee, États-Unis, 38138-1762
- The West Clinic (East Campus)
-
Nashville, Tennessee, États-Unis, 37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas, Texas, États-Unis, 75390-0001
- University of Texas Southwestern Medical Center
-
Dallas, Texas, États-Unis, 75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas, Texas, États-Unis, 75203-1260
- Liver Institute at Methodist Dallas
-
Dallas, Texas, États-Unis, 75235
- Moody Outpatient Center ? Parkland Health
-
Denison, Texas, États-Unis, 75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston, Texas, États-Unis, 77025-1669
- Kelsey Research Foundation
-
Houston, Texas, États-Unis, 77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray, Utah, États-Unis, 84107-5741
- Intermountain Healthcare
-
St. George, Utah, États-Unis, 84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church, Virginia, États-Unis, 22042
- Inova Schar Cancer Institute
-
Richmond, Virginia, États-Unis, 23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond, Virginia, États-Unis, 23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98101
- Virginia Mason Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Autres noms:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
Délai: Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trials, Hoffmann-La Roche
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Maladies du système digestif
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Carcinome
- Conditions pathologiques, signes et symptômes
- Carcinome hépatocellulaire
- Tumeurs du foie
- Fibrose
- Maladies du foie
- Foie gras
- Tumeurs du système digestif
- Acides aminés, peptides et protéines
- Protéines
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Bévacizumab
- atézolizumab
Autres numéros d'identification d'étude
- ML44719
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .